Overview

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2023-01-13
Target enrollment:
Participant gender:
Summary
This is a phase I, First-in-Human study in healthy participants, performed at a single study center, consisting of 2 parts: Part 1 is a single ascending dose (SAD) study and Part 2 is a multiple ascending dose (MAD) study.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca